Return to homepagePandemic Pact

Macrophage-targeting Nanoplatforms as Immunotherapy against Pulmonary Infections

Grant number: Sub no: 706658, award: 2 R01 AI132413-06

Grant search

Key facts

  • Disease

    Bacterial infection caused by Klebsiella pneumonia

  • Start & end year

    2024
    2025

  • Known Financial Commitments (USD)

    $247,196.84

  • Funder

    Estonian Research Council

  • Principal Investigator

    Teesalu Tambet

  • Research Location

    Estonia

  • Lead Research Institution

    University of Tartu

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

This project aims to develop a targeting strategy involving macrophage-targeting peptide ligands for targeted delivery of nanoplatforms that carry RNA therapeutics. Deploying existing or newly discovered peptides and deploying design rules from three broad classes of nanoparticles (lipid-based, tandem peptide-based, and mesoporous silicon-based) and it will identify an optimal nanoplatform to treat in vivo carbapenem-resistant Klebsiella pneumoniae (CRKP), Aspergillus fumigatus, and influenza A pneumonia.